We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2025

Session

Saturday
May 03
15:15 - 16:15
Stolz 1
Lower GI 2
Calogero Casà, Italy;
Kyubo Kim, Korea Republic of
Mini-Orals are presented at one of the sessions scheduled in the two mini-oral theatres. Each author will present a 4-slide PowerPoint orally for 4 minutes, followed by 3 minutes for discussion. Sessions will be recorded and made available via the online platform and mobile app.
Mini-Orals
Clinical
GI
15:15 - 15:22
Results of a phase II study of total neoadjuvant therapy for locally advanced rectal cancer(ClinicalTrials.gov No.: NCT04543695)
Huiying Ma, China
E25-1481
15:22 - 15:29
Habitat-based MRI radiomics for survival prediction in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy
Yanqi Huang, The Netherlands
E25-2002
15:29 - 15:36
Neoadjuvant Chemoradiotherapy with Simultaneous Integrated Boost for Stage II/III Rectal Adenocarcinoma: 9-year Outcomes of a Phase II Study
Haoyue Li, China
E25-2654
15:36 - 15:43
Short-course radiotherapy versus chemoradiotherapy in total neoadjuvant therapy of rectal cancer – A multicenter analysis of outcomes and toxicity
Georg Wurschi, Germany
E25-2182
15:43 - 15:50
Radiotherapy followed by CAPOX and Tislelizumab in MSS locally advanced rectal cancer with resectable metastases: Results of the MIRACLE-1 study
Menglong Zhou, China
E25-3785
15:50 - 15:57
Radiotherapy for rectal NEC treated with surgery and chemotherapy: a population-based cohort study
xiaojun Liu, China
E25-3212
15:57 - 16:04
The prognostic value of circulating cell-free DNA dynamics during chemoradiotherapy in squamous cell carcinomas of the anus
Anne Vittrup Jakobsen, Denmark
E25-3400
16:04 - 16:11
De-escalating Anal Cancer Treatment (DeACT) in co-morbid and frail patients: A retrospective UK national service evaluation.
Hamish Sinclair, United Kingdom
E25-1435